BiotechTube
Home/Sylentis/Andreas Segerros
AS

Andreas Segerros

Chief Executive Officer

Sylentis

Therapeutic Areas

Ophthalmology

Sylentis Pipeline

DrugIndicationPhase
TivanisiranDry Eye DiseasePhase 2/3
SYL1801Age-Related Macular Degeneration (AMD)Phase 2a